TW202124718A - 使用環狀dna將抗原特異性受體基因導入t細胞基因組之方法 - Google Patents

使用環狀dna將抗原特異性受體基因導入t細胞基因組之方法 Download PDF

Info

Publication number
TW202124718A
TW202124718A TW109139772A TW109139772A TW202124718A TW 202124718 A TW202124718 A TW 202124718A TW 109139772 A TW109139772 A TW 109139772A TW 109139772 A TW109139772 A TW 109139772A TW 202124718 A TW202124718 A TW 202124718A
Authority
TW
Taiwan
Prior art keywords
vector
nucleic acid
sequence
antigen receptor
nuclease
Prior art date
Application number
TW109139772A
Other languages
English (en)
Chinese (zh)
Inventor
一戸辰夫
山本卓
佐久間哲史
本庶仁子
川瀬孝和
西澤正俊
鈴木隆二
馬郡健太
佐藤寛之
Original Assignee
國立大學法人廣島大學
日商組庫創世紀股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人廣島大學, 日商組庫創世紀股份有限公司 filed Critical 國立大學法人廣島大學
Publication of TW202124718A publication Critical patent/TW202124718A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW109139772A 2019-11-14 2020-11-13 使用環狀dna將抗原特異性受體基因導入t細胞基因組之方法 TW202124718A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019206448 2019-11-14
JP2019-206448 2019-11-14

Publications (1)

Publication Number Publication Date
TW202124718A true TW202124718A (zh) 2021-07-01

Family

ID=75912989

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109139772A TW202124718A (zh) 2019-11-14 2020-11-13 使用環狀dna將抗原特異性受體基因導入t細胞基因組之方法

Country Status (6)

Country Link
US (1) US20230250415A1 (cg-RX-API-DMAC7.html)
EP (1) EP4060038A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2021095847A1 (cg-RX-API-DMAC7.html)
CN (1) CN114901812A (cg-RX-API-DMAC7.html)
TW (1) TW202124718A (cg-RX-API-DMAC7.html)
WO (1) WO2021095847A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI921044B (zh) * 2025-02-12 2026-04-01 宏碁股份有限公司 以胺基酸與來源蛋白關係產生負樣本的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59942B2 (ja) 1974-01-11 1984-01-09 株式会社日立製作所 ホウデンガタイオンゲンヨウデンゲン
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US20160264995A1 (en) * 2013-11-06 2016-09-15 Hiroshima University Vector for Nucleic Acid Insertion
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
JP6246258B2 (ja) 2016-04-25 2017-12-13 国立大学法人広島大学 Dna結合ドメインを含むポリペプチド
WO2018025206A1 (en) * 2016-08-02 2018-02-08 Kyoto University Method for genome editing
TWI814745B (zh) * 2017-10-10 2023-09-11 國立大學法人廣島大學 使用效應T細胞(Teff)抗原受體之抗原特異性控制性T細胞(Treg)之製出技術
CN117820491A (zh) * 2017-10-10 2024-04-05 国立大学法人广岛大学 使用铂talen的t细胞受体的完全取代技术
SG11202003798TA (en) * 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
JP7045643B2 (ja) 2018-05-28 2022-04-01 日本電気硝子株式会社 ガラス物品の製造方法及び製造装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI921044B (zh) * 2025-02-12 2026-04-01 宏碁股份有限公司 以胺基酸與來源蛋白關係產生負樣本的方法

Also Published As

Publication number Publication date
WO2021095847A1 (ja) 2021-05-20
EP4060038A4 (en) 2024-07-10
US20230250415A1 (en) 2023-08-10
JPWO2021095847A1 (cg-RX-API-DMAC7.html) 2021-05-20
EP4060038A1 (en) 2022-09-21
CN114901812A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
US12570982B2 (en) Altering gene expression in modified T cells and uses thereof
CN109803983B (zh) 靶向nkg2dl的特异性嵌合抗原受体t细胞,其制备方法和应用
US11952408B2 (en) HPV-specific binding molecules
JP7190096B2 (ja) 遺伝子編集t細胞及びその使用
CN108174604B (zh) 用于实体瘤靶向的双特异性car t细胞
AU2016349280B2 (en) Methods and compositions for gene editing in hematopoietic stem cells
JP2023516008A (ja) キメラ抗原受容体発現細胞を作製する方法
JP2022515290A (ja) 改変t細胞、その調製方法および使用
BR112020007710A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
US20190030073A1 (en) Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
CA3168932A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
TW202003845A (zh) 增強功能之經修飾免疫細胞及其篩選方法
CN113454117A (zh) Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途
EP3704251A2 (en) Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
TW201903145A (zh) 將基因編輯用於產生通用型t細胞受體重導向的t細胞以進行輸入免疫治療的用途
BR112020020073A2 (pt) Células t que expressam um receptor recombinante, polinucleotídeos relacionados e métodos
CA3162272A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
KR20190102259A (ko) 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
CN108174607A (zh) 用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
CN109153975A (zh) 制备嵌合抗原受体表达细胞的方法
JP2018532426A (ja) リンパ球における高レベル且つ安定な遺伝子移入のための方法
WO2020095107A1 (en) Anti-cd33 immune cell cancer therapy
WO2018205926A1 (zh) 经修饰的t细胞、其制备方法及用途
WO2021197391A1 (zh) 一种制备经修饰的免疫细胞的方法
CN117597358A (zh) 用于治疗her2阳性癌症的组合物和方法